EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

MTM1 overexpression prevents and reverts BIN1-related centronuclear myopathy

Quentin Giraud iD, Coralie Spiegelhalter, Nadia Messaddeq, Jocelyn Laporte iD

Brain · 2023

DOI: 10.1093/brain/awad251 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, 2023. Verfasst von Quentin Giraud und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), CNRS UMR7104, INSERM U1258, Université de Strasbourg, 67404, Illkirch, France. Hauptthemen laut MEDLINE: Muscle, Skeletal, Myopathies, Structural, Congenital, Protein Tyrosine Phosphatases, Non-Receptor. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: IdEx Unistra, framework of the French Investments for the Future Program, Fondation Recherche Médicale.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Centronuclear and myotubular myopathies (CNM) are rare and severe genetic diseases associated with muscle weakness and atrophy as well as intracellular disorganization of myofibres. The main mutated proteins control lipid and membrane dynamics and are the lipid phosphatase myotubularin (MTM1), and the membrane remodelling proteins amphiphysin 2 (BIN1) and dynamin 2 (DNM2). There is no available therapy. Here, to validate a novel therapeutic strategy for BIN1- and DNM2-CNM, we evaluated adeno-associated virus-mediated MTM1 (AAV-MTM1 ) overexpression in relevant mouse models. Early systemic MTM1 overexpression prevented the development of the CNM pathology in Bin1mck−/− mice, while late intramuscular MTM1 expression partially reverted the established phenotypes after only 4 weeks of treatment. However, AAV-MTM1 injection did not change the DNM2-CNM mouse phenotypes. We investigated the mechanism of the rescue of the myopathy in BIN1-CNM and found that the lipid phosphatase activity of MTM1 was essential for the rescue of muscle atrophy and myofibre hypotrophy but dispensable for the rescue of myofibre disorganization including organelle mis-position and T-tubule defects. Furthermore, the improvement of T-tubule organization correlated with normalization of key regulators of T-tubule morphogenesis, dysferlin and caveolin. Overall, these data support the inclusion of BIN1-CNM patients in an AAV-MTM1 clinical trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscle, SkeletalMyopathies, Structural, CongenitalProtein Tyrosine Phosphatases, Non-ReceptorAnimalsHumansMiceAdaptor Proteins, Signal TransducingDynamin IILipidsMuscular AtrophyMutationNuclear ProteinsPhenotypeTumor Suppressor ProteinsGenetic Therapy

Stichwörter der Autor:innen

congenital myopathygene therapymTORneuromuscular diseaseskeletal muscle

Substanzen

Adaptor Proteins, Signal TransducingBIN1 protein, humanDynamin IILipidsNuclear ProteinsTumor Suppressor ProteinsmyotubularinProtein Tyrosine Phosphatases, Non-Receptor

Autor:innen und Institutionen

  • Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), CNRS UMR7104, INSERM U1258, Université de Strasbourg, 67404, Illkirch, France.

ORCID-Profile: Quentin Giraud, Jocelyn Laporte

Förderung

  • IdEx Unistra
  • framework of the French Investments for the Future Program
  • Fondation Recherche Médicale
  • AFM-Téléthon

Zitieren

APA

Giraud, Q., Spiegelhalter, C., Messaddeq, N., & Laporte, J. (2023). MTM1 overexpression prevents and reverts BIN1-related centronuclear myopathy. Brain. https://doi.org/10.1093/brain/awad251

Vancouver

Giraud Q, Spiegelhalter C, Messaddeq N, Laporte J. MTM1 overexpression prevents and reverts BIN1-related centronuclear myopathy. Brain. 2023. doi:10.1093/brain/awad251

BibTeX
@article{Giraud2023,
  author = {Giraud, Quentin and Spiegelhalter, Coralie and Messaddeq, Nadia and Laporte, Jocelyn},
  title = {MTM1 overexpression prevents and reverts BIN1-related centronuclear myopathy},
  journal = {Brain},
  year = {2023},
  doi = {10.1093/brain/awad251}
}
Kostenlos starten →